(GMAB) Genmab A/S Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GMAB) Genmab A/S Complete Analysis Pack
Go Beyond the Preview—Access the Full Strategic Report
This Genmab A/S Porter’s Five Forces Analysis helps you quickly assess the company’s competitive landscape, including rivalry, buyer and supplier power, substitutes, and new entrants. The page already shows a real preview of the analysis, so you can see the style and content before buying. Purchase the full version for the complete ready-to-use report.
Suppliers Bargaining Power
Specialized biologics inputs
Genmab’s bargaining power with suppliers is high because its biologics work depends on specialized cell lines, reagents, antibodies, and sterile materials that are not fully commoditized. In 2025, Genmab reported strong R&D spending, which makes any supplier delay or failure more costly. In biologics, a missed lot can cut yield, hurt quality, and push back timelines.
Contract manufacturing reliance
Genmab A/S depends on a small set of CDMOs for advanced antibody production and fill-finish, so supplier power is high. Switching a validated biologics site can take 12 to 18 months, and regulators must re-approve key process changes, which weakens Genmab A/S’s leverage. That makes capacity, quality, and batch-release timing critical cost and risk drivers.
Partner-controlled assets
Genmab A/S still relies on partner-controlled assets, with key programs co-developed with Janssen, AbbVie, Seagen, and others. That gives partners leverage over timelines, economics, and even trial design, so Genmab A/S does not fully control several core assets. The result is a higher supplier power risk, especially when a partner can slow a 2025/2026 program or reshape its value split.
Clinical and regulatory service providers
Clinical trial sites, CROs, and specialty labs are key to Genmab A/S’s pipeline, especially in oncology where site capacity is tight. In 2025, the global CRO market was about $85 billion, and oncology remained the biggest trial area, so experienced suppliers can push pricing up. If sites or labs are short, Genmab A/S can miss milestone timing.
- High supplier power in oncology
- Capacity shortages raise costs
- Delays can hit milestones
Moderate but not dominant supplier leverage
Genmab A/S’s supplier leverage is moderate because it is a large, credible biopharma buyer, with FY2024 revenue of about DKK 17.4 billion, so it can press harder on contract terms than small biotech firms. Still, biologics work needs specialized CDMO, assay, and cold-chain capacity, which keeps key suppliers important.
- Large scale weakens supplier pricing power
- Specialized biologics inputs keep leverage meaningful
- Overall supplier power stays moderate
This balance matters: Genmab can switch some vendors, but qualified infrastructure and regulated production steps limit easy substitution, so supplier pressure does not disappear.
Genmab’s Supply Chain Leverage Is Limited by Scarce CDMO Capacity
Genmab A/S faces high supplier power because its 2025 pipeline still depends on scarce CDMOs, sterile biologics inputs, and partner-controlled assets. Switching a validated biologics site can take 12 to 18 months, so delays or batch failures can raise cost and push back milestones. Even with about DKK 17.4 billion in FY2024 revenue, Genmab A/S has limited leverage where capacity is tight.
| Key supplier risk | Latest data |
|---|---|
| Genmab A/S revenue | DKK 17.4 billion |
| Site switch time | 12 to 18 months |
| CRO market size | About $85 billion in 2025 |
What is included in the product
Detailed Word Document
Assesses Genmab A/S’s competitive pressures, supplier and buyer power, and entry threats shaping its market position.
Customizable Excel Spreadsheet
Quickly spot Genmab A/S’s competitive pressures in one clear view—saving time on strategic analysis.
Reference Sources
Provides a concise source trail that boosts credibility and helps decision-makers verify Genmab A/S assumptions fast.
Customers Bargaining Power
Powerful payers and reimbursement systems
Genmab sells into markets where payers control access: Medicare covers about 66 million people in the U.S., and national systems like NICE can decide if a drug is reimbursed. These buyers can force lower net prices, tighter formulary placement, and prior-approval rules. That makes bargaining power high in oncology and chronic specialty care, where payers watch outcomes and total spend closely.
Hospital and specialist gatekeepers
Genmab A/S therapies often reach patients through oncology centers and specialist clinics, so hospital formularies and protocol committees act as gatekeepers. That means even when clinical benefit is clear, adoption can hinge on local access rules, not just prescribing demand. In 2025, this gave large institutional buyers real leverage on price, volume, and timing.
High value does not remove price scrutiny
Genmab A/S treats severe cancers and blood disorders, so premium pricing is possible, but buyers still push back hard. Darzalex still topped USD 10 billion in annual sales, showing strong value, yet payers demand proof on survival, safety, and total budget impact before they pay. That keeps customer bargaining power high even in rare-disease markets.
Limited switching once therapy starts
Once therapy starts, customer power falls because oncologists follow label rules, response data, and safety protocols, so switching can risk loss of benefit. That matters in biologics like Genmab A/S medicines, where a change can disrupt dosing and monitoring. Buyers still have leverage before start, when payers and hospitals set coverage and contract terms.
- Low switching after adoption
- Physician-led treatment choices
- High leverage at coverage stage
Buyer power is moderate to high
Genmab can still command strong pricing when a therapy shows clear clinical differentiation, but buyer power is constrained by cost discipline. In the U.S., the 3 largest PBMs control about 80% of prescriptions, and large hospital systems and national payers negotiate hard on rebates and access.
- Strong differentiation lifts pricing power.
- Concentrated payers press for discounts.
- Buyer power is moderate to high.
Genmab Faces Strong Buyer Power Despite Darzalex’s Blockbuster Sales
Genmab A/S faces high customer power because 3 U.S. PBMs control about 80% of prescriptions, and national payers can block or delay access. Darzalex still topped USD 10 billion in annual sales, but buyers still demand survival and budget proof before paying. Power eases after start, yet stays high at coverage and rebate talks.
| Buyer lever | Data |
|---|---|
| U.S. PBM concentration | About 80% of prescriptions |
| Darzalex annual sales | Above USD 10 billion |
| Access gate | Hospital and payer approval |
Preview the Actual Deliverable
Genmab A/S Porter's Five Forces Analysis
This preview shows the exact Genmab A/S Porter’s Five Forces Analysis you’ll receive after purchase—no mockups, no placeholders, just the final document. It’s professionally written, fully formatted, and ready to use immediately after checkout. What you see here is the same file you’ll download, so you can buy with confidence knowing there are no surprises.
Rivalry Among Competitors
Dense oncology competition
Genmab faces dense oncology rivalry: antibodies, bispecifics, ADCs, and immunotherapies all move fast, so rival launches can hit the same indication quickly. Johnson & Johnson reported Darzalex sales of $11.7bn in 2024, showing how large incumbents can defend key cancer markets. With many late-stage programs chasing the same tumor types, pricing and share can shift fast.
Big pharma and biotech rivals
Genmab competes with Big Pharma and fast-moving biotech firms, so rivalry is high across both marketed drugs and pipeline assets. Larger rivals can fund bigger trials, broader sales teams, and more M&A, which can pressure Genmab on speed, pricing, and partner deals. That matters in antibodies and oncology, where several global players are chasing the same targets and patient groups.
Rapid innovation cycles
Genmab has 6 marketed products, but rapid readouts can still shift share fast. A rival’s better efficacy, safety, or dosing can blunt demand overnight, so each new data drop matters. That is why Genmab must keep pipeline depth and launch speed high to defend its lead.
Partnered programs create overlap
Partnered programs raise competitive rivalry because some Genmab molecules sit in crowded target spaces, so rivals and partners chase the same first-approval and label-expansion wins. In FY2025, that pressure was clear in antibody and ADC programs where speed, data depth, and broader labels can decide value fast. Being first or best still matters most in these races.
- Crowded targets increase race risk.
- First approval can set the bar.
- Label breadth drives follow-on value.
Rivalry is high
Rivalry is high: Genmab’s 2025 revenue rose to about DKK 17bn, but that scale still sits in crowded oncology and immunology markets where rivals like Roche, Pfizer, and AbbVie push hard. Strong science and partners help, yet they do not reduce crowding; Genmab still needs clear clinical wins, fast launches, and smart life cycle management to defend share.
Its 2025 R&D spend near DKK 6bn shows the arms race is intense.
- Clinical edge matters most.
- Speed can decide share.
- Life cycle management is key.
Genmab Faces Fierce Competition as R&D Spending Stays High
Competitive rivalry is high for Genmab A/S because oncology and immunology markets are crowded, and rivals can move fast on efficacy, dosing, and label breadth. Genmab A/S reported 2025 revenue of about DKK 17bn and R&D of nearly DKK 6bn, underscoring the spend needed to keep pace.
| Metric | 2025 |
|---|---|
| Revenue | ~DKK 17bn |
| R&D spend | ~DKK 6bn |
| Risk | High rivalry |
Substitutes Threaten
Other treatment modalities
Patients can also be treated with chemotherapy, targeted small molecules, ADCs, cell therapy, or surgery, so Genmab A/S faces several direct substitutes. In oncology, 5 major treatment paths can compete with an antibody-based regimen, and each one can win in a different line of care or tumor type. The broader the approved option set, the stronger the substitution threat for Genmab A/S therapies.
Same class competition
Genmab A/S faces direct same-class substitution because many of its drugs sit in crowded antibody and immunotherapy markets. In 2024, DARZALEX, a key benchmark in this space, generated about USD 11.7 billion in sales for Johnson & Johnson, showing how fast prescribers can shift to a better-known rival if dosing or safety looks stronger. That keeps switching pressure high across the class.
Guideline and protocol substitution
Guideline and protocol substitution is a real risk for Genmab A/S because hospitals can move to preferred regimens as new data and payer rules change. That matters most in oncology, where one label update or reimbursement shift can steer use away from a Genmab therapy. Genmab A/S still depends on strong clinical proof and access coverage to keep its drugs in standard pathways.
Supportive care and watchful waiting
Supportive care and watchful waiting can delay or avoid drug use in low-risk or slow-moving disease, so they cut near-term demand for some Genmab A/S therapies. The impact is modest in severe cancers, but it still matters in selected settings where active surveillance is common.
- About 20 million new cancer cases a year globally
- Lower-risk cases can be observed first
- Best for frail or indolent disease
- Less pressure on branded therapy sales
That makes substitutes a real, but not dominant, force for Genmab A/S.
Substitution threat is moderate
Genmab A/S sells therapies for serious cancers and other severe diseases, so patients and doctors cannot switch easily when a drug works. Still, oncology has several substitutes, including ADCs, bispecifics, checkpoint inhibitors, CAR-T, and small molecules, so alternatives remain real. That makes substitution threat moderate. In 2025, the global oncology market stayed above $250 billion, keeping competition broad.
- Severe disease limits easy switching
- Multiple oncology modalities compete
- Overall threat stays moderate
Genmab Faces Moderate Substitute Pressure in Oncology
Threat of substitutes for Genmab A/S is moderate because oncology patients can still move to chemotherapy, targeted small molecules, ADCs, CAR-T, surgery, or watchful waiting. In 2024, Johnson & Johnson reported DARZALEX sales of about USD 11.7 billion, which shows how fast prescribers can shift within the same class. Payer rules and guideline changes can also redirect use away from Genmab A/S drugs.
| Substitute | Impact |
|---|---|
| ADC and bispecific rivals | High |
| Chemo and small molecules | High |
| Watchful waiting | Low to medium |
Entrants Threaten
Very high development barriers
Biopharmaceutical entry is costly: drug development often takes 10-15 years, and only about 1 in 10 candidates reaches approval. That means new rivals need deep capital, top scientific talent, and long patience before any revenue.
For Genmab A/S, this makes the threat of new entrants very low even in 2026, because failed trials burn cash fast and can wipe out years of work. The high fail rate is the real moat.
Regulatory and quality hurdles
New entrants must satisfy regulators like the FDA and EMA and prove consistent biologics manufacturing, which means locked process control, comparability data, and expensive validation. For Genmab A/S, that bar is high because antibody products are sensitive to small process changes, so even minor drift can force new studies and delays. The result is slower entry, higher upfront capex, and a tougher path to market.
IP and partnership barriers
Genmab A/S’s DuoBody and HexaBody platforms, plus deep partner ties with AbbVie, Johnson & Johnson, and AbbVie, create real IP barriers for new entrants. Building similar antibody know-how usually takes licensed tech, clinical data, and long deal cycles, so independent entry is hard. In 2024, Genmab A/S generated DKK 18.7 billion in revenue, underscoring the scale of its collaboration moat.
Scale and commercialization challenges
Launching oncology biologics needs medical affairs, market access, and a specialty sales team, and those build costs can run into hundreds of millions before one product scales. That makes entry hard for young firms. Genmab A/S also has trust with doctors and payers, plus a larger global base, so it can commercialize faster and at lower unit cost.
- Heavy launch spend blocks small firms
- Payer access slows weak entrants
- Genmab A/S scales faster
- Credibility lowers adoption risk
In 2025/2026, oncology buyers still favor firms with proven launch teams, real-world evidence, and reimbursement reach.
Threat of new entrants is low to moderate
Threat of new entrants for Genmab A/S is low to moderate. Academic spinouts and platform biotech firms can still appear, especially with AI and modular antibody tools, but they face heavy capital needs, long clinical timelines, and strict FDA/EMA review. In 2025, new drug R&D still often requires hundreds of millions of dollars and 8 to 12 years before approval.
- AI lowers discovery barriers
- Trials and regulation stay costly
- Scale and IP still favor incumbents
Genmab’s moat keeps new entrants out in 2025/2026
Threat of new entrants for Genmab A/S stays low in 2025/2026. Biopharma needs 10-15 years, about a 90% failure rate, and heavy FDA/EMA validation, while Genmab A/S also has strong DuoBody/HexaBody IP and partner scale.
| Barrier | Data |
|---|---|
| Development time | 10-15 years |
| Approval success | ~10% |
| Genmab A/S revenue | DKK 18.7B in 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.